← CASI Pharmaceuticals, Inc. (CASI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CASI Pharmaceuticals, Inc. (CASI)
Pharmaceutical Preparations · market cap $57M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
11
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
CASI Pharmaceuticals (CASI) is a small-cap pharmaceutical company with a market cap of approximately $57M and 233 employees. Its pipeline consists entirely of Phase 2 assets across oncology and hematology indications, led by pemetrexed for advanced cancer, with no upcoming catalysts disclosed and no recent catalysts on record. The company carries no analyst coverage and limited public financial disclosure, making fundamental valuation highly uncertain.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sunitinib Malate | Phase 2 | Metastatic Renal Cell Carcinoma |
| recombinant human Angiostatin protein | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| CID-103 | Phase 2 | Chronic Immune Thrombocytopenia |
| Panzem NCD | Phase 2 | Recurrent Glioblastoma Multiforme |
| ENMD-2076 | Phase 2 | Ovarian Cancer |
| MKC-1 | Phase 2 | Ovarian Cancer |
| Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | Ovarian Cancer |
| Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Phase 2 | Carcinoid Tumor |
| 2-methoxyestradiol | Phase 2 | Relapsed Multiple Myeloma |
| Panzem Nanocrystal Colloidal Dispersion | Phase 2 | Recurrent Glioblastoma Multiforme |
| Panzem® NCD | Phase 2 | Prostate Cancer |
Price & technical context
3-month
+0.0%
6-month
+0.0%
12-month
+0.0%
52-wk range
$3.70–$3.70
vs 50-day MA
+0.0%
vs 200-day MA
-0.0%
Realized vol
0.0%
Max drawdown
-62.8%
Daily closes through 2026-02-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CASI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.